Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2013 3
2014 6
2015 17
2016 9
2017 5
2018 13
2019 5
2020 12
2021 17
2022 19
2023 17
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. van Rhee F, et al. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
BACKGROUND: Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and effi …
BACKGROUND: Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production o …
Recent Advances in Castleman Disease.
Hoffmann C, Hentrich M, Tiemann M, Rosenwald A, Weber F, Willenbacher W, Hübel K. Hoffmann C, et al. Oncol Res Treat. 2022;45(11):693-704. doi: 10.1159/000526640. Epub 2022 Oct 11. Oncol Res Treat. 2022. PMID: 36219975 Review.
BACKGROUND: Castleman disease (CD) encompasses a spectrum of rare disorders with characteristic histopathological features. ...KEY MESSAGES: We herein summarize recent advances in diagnosis, treatment, and novel insights into the pathogenesis of this disease. …
BACKGROUND: Castleman disease (CD) encompasses a spectrum of rare disorders with characteristic histopathological features. .. …
Therapy of Castleman's disease with siltuximab - case report and review of literature.
Adam Z, Zeman D, Chodacki A, Pour L, Horváth T, Benda P, Adamová Z, Krejčí M, Tomíška M, Boichuk I, Král Z. Adam Z, et al. Klin Onkol. 2023 Winter;37(4):320-329. Klin Onkol. 2023. PMID: 38195387 Review. English.
BACKGROUND: Idiopathic multicentric Castleman disease (iMCD) is characterized by constitutional symptoms, enlarged lymph nodes and laboratory test abnormalities, which are primarily related to the overproduction of interleukin-6 (IL-6). ...Siltuximab demonstr …
BACKGROUND: Idiopathic multicentric Castleman disease (iMCD) is characterized by constitutional symptoms, enlarged lymph nodes …
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
Lyseng-Williamson KA. Lyseng-Williamson KA. BioDrugs. 2015 Dec;29(6):399-406. doi: 10.1007/s40259-015-0142-5. BioDrugs. 2015. PMID: 26394632 Review.
Siltuximab (Sylvant), an interleukin (IL)-6 chimeric immunoglobulin G monoclonal antibody, is a currently the only agent approved to treat human idiopathic (herpesvirus-8 negative) multicentric Castleman disease (iMCD), which is a rare lymphoproliferative dis …
Siltuximab (Sylvant), an interleukin (IL)-6 chimeric immunoglobulin G monoclonal antibody, is a currently the only agent approved to …
Review of siltuximab in the treatment of multicentric Castleman's disease.
Sarosiek S, Shah R, Munshi NC. Sarosiek S, et al. Ther Adv Hematol. 2016 Dec;7(6):360-366. doi: 10.1177/2040620716653745. Epub 2016 Jun 23. Ther Adv Hematol. 2016. PMID: 27904739 Free PMC article. Review.
Castleman's disease (CD) is a rare lymphoproliferative disorder that has multiple histologic patterns, as well as two distinct clinical forms: unicentric or multicentric. Multicentric Castleman's disease (MCD) may have mild symptoms in so …
Castleman's disease (CD) is a rare lymphoproliferative disorder that has multiple histologic patterns, as well as two d …
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
Fajgenbaum DC, Kurzrock R. Fajgenbaum DC, et al. Immunotherapy. 2016;8(1):17-26. doi: 10.2217/imt.15.95. Epub 2015 Dec 4. Immunotherapy. 2016. PMID: 26634298 Review.
Human herpes virus-8 (HHV-8)-negative or idiopathic multicentric Castleman disease (iMCD) is a rare and deadly disorder that sits at the nexus of hematology/oncology, virology and immunology. ...In the first ever randomized, placebo-controlled trial in iMCD, silt …
Human herpes virus-8 (HHV-8)-negative or idiopathic multicentric Castleman disease (iMCD) is a rare and deadly disorder that s …
Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.
Sitenga J, Aird G, Ahmed A, Silberstein PT. Sitenga J, et al. Patient Relat Outcome Meas. 2018 Jan 12;9:35-41. doi: 10.2147/PROM.S140011. eCollection 2018. Patient Relat Outcome Meas. 2018. PMID: 29391839 Free PMC article. Review.
Multicentric Castleman's disease (MCD) is a rare, widespread lymphoproliferative disorder and a life-threatening disease involving hyperactivity of the immune system, excessive proinflammatory cytokine release, immune cell proliferation, and organ syst …
Multicentric Castleman's disease (MCD) is a rare, widespread lymphoproliferative disorder and a life-threatening dis …
Siltuximab: a new option for the management of Castleman's disease.
Barquero N. Barquero N. Drugs Today (Barc). 2015 Jan;51(1):21-8. doi: 10.1358/dot.2015.51.1.2234002. Drugs Today (Barc). 2015. PMID: 25685858 Review.
Recent phase II clinical studies in patients with multicentric Castleman's disease have shown the efficacy and safety of siltuximab in patients with this condition. Results from this study led to the recent approval of siltuximab for the treatme …
Recent phase II clinical studies in patients with multicentric Castleman's disease have shown the efficacy and safety o …
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A, Fajgenbaum DC. van Rhee F, et al. Blood Adv. 2022 Aug 23;6(16):4773-4781. doi: 10.1182/bloodadvances.2022007112. Blood Adv. 2022. PMID: 35793409 Free PMC article. Clinical Trial.
Idiopathic multicentric Castleman disease (iMCD) is a rare heterogeneous disorder involving multicentric lymphadenopathy, systemic inflammation, and cytokine-driven organ dysfunction. Despite the approval of siltuximab, a monoclonal antibody against interleuk …
Idiopathic multicentric Castleman disease (iMCD) is a rare heterogeneous disorder involving multicentric lymphadenopathy, syst …
Siltuximab.
[No authors listed] [No authors listed] 2016 Apr 9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2016 Apr 9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644237 Free Books & Documents. Review.
Siltuximab is a chimeric human-mouse monoclonal antibody to interleukin-6 which is used in the therapy of Castleman disease. Siltuximab commonly causes mild serum aminotransferase elevations which are usually short lived and asymptomatic, but it has no …
Siltuximab is a chimeric human-mouse monoclonal antibody to interleukin-6 which is used in the therapy of Castleman disease …
117 results